Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $8.02 USD
Change Today +0.45 / 5.94%
Volume 7.9M
As of 3:33 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Daniel M. Bollag Ph.D.

Senior Vice President of Regulatory Affairs and Quality,Ariad Pharmaceuticals Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 1 different industries.

As of Fiscal Year 2014


Dr. Daniel M. Bollag, Ph.D. has been the Senior Vice President of Regulatory Affairs & Quality at Ariad Pharmaceuticals Inc. since January 2009. Dr. Bollag leads regulatory strategy and operations, including the anticipated filing of a new drug application for oral deforolimus in patients with metastatic sarcomas and also responsible for directing the Ariad Pharmaceuticals global quality systems. He has fifteen years experience in the pharmaceutical industry, of which ...

Read Full Background

Corporate Headquarters*

26 Landsdowne Street
Cambridge, Massachusetts 02139

United States

Phone: 617-494-0400
Fax: 617-494-8144

Board Members Memberships*

There is no Board Members Memberships data available.


Cornell University
Unknown/Other Education
Princeton University
Pennsylvania State University
Pennsylvania State University

Other Affiliations*

Annual Compensation*

Total Annual Compensation$647,000

Stock Options*

Restricted Stock Awards$650,320
All Other Compensation$32,370
Exercised Options26,250
Exercised Options Value$129,087
Exercisable Options84,583
Exercisable Options Value$62,663
Unexercisable Options44,667
Total Value of Options$191,749
Total Number of Options155,500

Total Compensation*

Total Annual Cash Compensation$679,370
Total Short Term Compensation$647,000
Other Long Term Compensation$682,690
Total Calculated Compensation$1,329,690
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARIA:US $8.02 USD +0.45


Ron Squarer BSc (Biochemistry), MBAChief Executive Officer and Director
Array BioPharma Inc.
Michael M. Morrissey Ph.D.Chief Executive Officer, President and Director
Exelixis, Inc.
Werner Lanthaler MBA,MPAChief Executive Officer and Member of Management Board
Evotec AG
Adelene Q. Perkins Chairman of The Board, Chief Executive Officer and President
Infinity Pharmaceuticals, Inc.
Aijaz Tobaccowalla Managing Director, Director, Member of Board Administrative & Share Transfer Committee, Member of Nomination & Remuneration Committee, Member of Corporate Social Responsibility Committee and Member of Audit Committee
Pfizer Limited
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARIAD PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at